Nemtabrutinib is a small molecule commercialized by Merck, with a leading Phase III program in Relapsed Chronic Lymphocytic Leukemia (CLL);Refractory Chronic Lymphocytic Leukemia (CLL). According to Globaldata, it is involved in 12 clinical trials, of which 2 were completed, and 10 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Nemtabrutinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Nemtabrutinib is expected to reach an annual total of $31 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Nemtabrutinib Overview
Nemtabrutinib (ARQ-531) is under development for the treatment of arthritis, relapsed or refractory hematologic malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom macroglobulinemia, B-cell non-Hodgkin lymphoma, previously untreated mantle cell lymphoma, mantle cell lymphoma, marginal zone lymphoma and diffuse large B-cell lymphoma. It is administered orally. The drug candidate is prepared by using ArQule Kinase Inhibitor Platform (AKIP). This platform targets inactive forms of kinases that have pivotal roles in cancer and other diseases. The drug candidate acts by targeting tyrosine protein kinase BTK.
Merck Overview
Merck is a biopharmaceutical company with focus on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for the treatment of cardiovascular conditions, cancer, immune disorders, infectious and respiratory diseases, and diabetes, among others. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors, and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is headquartered in Rahway, New Jersey, the US.
The company reported revenues of (US Dollars) US$60,115 million for the fiscal year ended December 2023 (FY2023), an increase of 1.4% over FY2022. In FY2023, the company’s operating margin was 3%, compared to an operating margin of 30.3% in FY2022. In FY2023, the company recorded a net margin of 0.6%, compared to a net margin of 24.5% in FY2022.
The company reported revenues of US$16,112 million for the second quarter ended June 2024, an increase of 2.1% over the previous quarter.
For a complete picture of Nemtabrutinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
